Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Pyxis Oncology, Inc. (NASDAQ:PYXS) has received a consensus recommendation of “Moderate Buy” from the nine research firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $6.8571.

A number of analysts recently commented on PYXS shares. Wall Street Zen lowered Pyxis Oncology from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Wedbush assumed coverage on shares of Pyxis Oncology in a research report on Tuesday, May 5th. They set an “outperform” rating and a $6.00 target price for the company. Weiss Ratings cut Pyxis Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 30th. Finally, Leerink Partners reduced their target price on Pyxis Oncology from $9.00 to $7.00 and set an “outperform” rating on the stock in a report on Thursday, July 2nd.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PYXS. Maia Wealth LLC bought a new position in shares of Pyxis Oncology during the 4th quarter valued at about $25,000. Engineers Gate Manager LP acquired a new position in shares of Pyxis Oncology during the fourth quarter worth about $26,000. Fox Run Management L.L.C. acquired a new stake in Pyxis Oncology in the 4th quarter valued at approximately $26,000. Avanza Fonder AB acquired a new position in Pyxis Oncology during the 4th quarter worth approximately $31,000. Finally, XTX Topco Ltd acquired a new stake in shares of Pyxis Oncology in the second quarter valued at approximately $40,000. 39.07% of the stock is owned by institutional investors and hedge funds.

Pyxis Oncology Stock Performance

Shares of NASDAQ:PYXS opened at $2.61 on Tuesday. The business has a fifty day moving average of $2.17 and a 200-day moving average of $1.82. The firm has a market cap of $165.34 million, a PE ratio of -1.99 and a beta of 1.30. Pyxis Oncology has a twelve month low of $0.97 and a twelve month high of $5.55.

Pyxis Oncology (NASDAQ:PYXS) last announced its earnings results on Thursday, May 14th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02). On average, analysts anticipate that Pyxis Oncology will post -1.19 EPS for the current fiscal year.

About Pyxis Oncology

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.